Ivy League suicides, Princeton's 8th student death in 4 years expose crisis at elite schools
This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255).
The recent death of a Princeton University undergraduate student, just weeks away from completing his junior year, has prompted renewed conversation about how Ivy League schools handle mental health crises on campus.
Lauren Blackburn, 23, was an English major and creative writing minor from Indiana. He was missing for several days before authorities found him deceased in a lake. Officials have not released his cause of death or said if there was any foul play involved.
Blackburn was the third Princeton undergraduate student to die in two years and the eighth since 2021. Six of those deaths were determined to be suicides, as The Princetonian first reported.
Princeton Professor Yiyun Li, who directs the university's creative writing program, lost both of her sons to suicide, one of whom, James Li, was a Princeton student when he died in 2024.
Ivy League Schools Received $6.4B In Federal Funding In 2024
Read On The Fox News App
"What can parents do but give their children the space to be, and allow them to do what they need so that they can become more fully themselves?" Yiyun Li wrote in a New Yorker essay titled "The Deaths — And Lives — of Two Sons" published on March 23.
"And yet, despite the parents' efforts, and despite all the beings and doings that occur as the children grow, some among them die before their time. Children die, and they are not happy. And their parents can never know whether those children died because they were not happy, or whether they were not happy because they sensed, too early, that they must face their own deaths."
While mental health crises and suicides are not unique to Princeton, or Ivy League schools generally, experts say Ivy League students face distinct challenges and pressures while attending the country's most prestigious schools. Experts also say Ivy League institutions should be dedicating more funds to mental health resources than they do currently.
"I think it comes down to the demands, and I would say almost 100% of the time, the Ivy League schools have really high rigorous demands," Ivy Ellis, certified mental health therapist and Licensed Clinical Social Worker (LCSW) who regularly works with college students, told Fox News Digital. "Whereas at other universities, the demands can be lower in terms of just how much schoolwork is asked, like how many classes they have to take, how much homework they have, how many tests they have."
Ellis added her belief that while Ivy League schools do "care" about their students, "There's limited funding and limited resources that go towards mental health."
"So almost all the universities and Ivy League schools have counseling centers in place, and I know they're excellent, excellent counselors," she said. "They work really hard. There's just such a high number of students that need that support, and the number of counselors just doesn't really meet that level of support."
New Report Sounds Alarm On 'Staggering' Amount Of Foreign Money Pouring Into Us Universities
Dr. Victoria Grinman, a psychotherapist and owner of a private practice called Growing Kind Minds who also works with college students, told Fox News Digital that "colleges across the board are seeing mental health crises, unfortunate things happening and people struggling."
"So I don't think that it's necessarily just about Ivy League institutions. But we also have to be aware that when … a teen is entering into an Ivy League institution, there are some expectations and standards that differ. And with those standards comes a lot of self-expectations," she said.
None of the eight traditional Ivy League schools — Harvard, Yale, Princeton, Brown, Dartmouth, Cornell, the University of Pennsylvania and Columbia — responded to Fox News Digital's request for student death data between 2020 and the present, or what resources they offer students experiencing mental health crises.
At Dartmouth University, two students were found dead in the Connecticut River last year; one of those student's deaths has been attributed to a hazing incident. The university also saw four student deaths in 2021.
Following the two 2024 deaths of students, both of whom were Asian, now-graduates Daniel Lin and Deborah Jang penned an op-ed for The Dartmouth criticizing the school's response to the two tragedies as racist.
"A symptom of this invisible racism is that we ourselves become invisible — to others and to ourselves," they wrote. "...There was no lasting public discussion on the racialization of the two deaths. It's not lost on us that two Asian students died in three months. The College could have named this; they could have made an effort to reach out to the Asian community. This reality leaves me feeling like these conversations can only happen behind closed doors, mostly among Asian students."
Jewish College Students Say They're Scared To Go To Class, Blame Universities For Silence On Antisemitism
The authors added that "Dartmouth does not have even the bare minimum support for Asian students."
Last year, two Cornell University students were found on the same day in the Fall Creek Gorge, one of whom died while the other was hospitalized. The university saw a string of suicides around 2010, and one victim's father sued Cornell for negligence by not implementing appropriate suicide prevention measures related to the numerous bridges in the Ithaca, New York, area. He accepted a $100,000 settlement from the city in 2014, according to The Ithaca Journal.
"These bridges and adjacent cliffs have developed an iconic status for suicide due to multiple jumping suicides among enrolled Cornell students and other individuals," a summary of a 2024 case study reads. "Cornell University and the City of Ithaca have a unique challenge where multiple bridges and gorges collectively had become a 'hotspot' for suicide."
Jewish Harvard Students Speak Out After University Sues Trump Admin Over Funding Freeze
Yale recently faced a lawsuit following the 2021 suicide of first-year student Rachael Shaw-Rosenbaum accusing the university of discriminating against students with disabilities because it required students on mental health leaves to withdraw from Yale and reapply, according to The New York Times. Yale has since changed its policies.
Back in 2017, Columbia University saw a string of seven suicides between September and January of that year, as The New York Post reported at the time.
Harvard President Says He Has 'No Choice' But To Fight Trump Administration
Grinman noted that the college experience has changed drastically in recent years, "especially with social media and just what it's become."
"It's a place where people are actually launching into the next phase of development," Grinman said. "Everybody, even if they don't know what they want to do in college, they want to go to college because they want to have the college experience. It's where kids are starting their lives, right? They're learning how to live on their own, how to be in social groups, how to do things on their own. So it's a very, very sensitive time," she said.
Brown University Student Who Angered Non-faculty Employees For Doge-like Emails Faces Punishment From School
Students who may have been "big fish in a small pond" in high school may find that's not the case at a prestigious institution, "and there is some angst around comparison," she explained.
Ellis suggested more colleges and universities should offer "early intervention" resources, targeting mental health concerns before they develop into self-harm or suicidal ideation.
"If the universities could help facilitate these dialogues and make it less of a taboo to have mental health struggles, and then even maybe some systems in place for screening so that they're able to help these students earlier on so it doesn't get so intense that the students are just failing out of school or even engaging in really harmful behaviors," she said.
The eight Ivy League schools received a total of $6.4 billion in federal funding in 2024. Financial statements from Columbia University show that it received $1.3 billion in federal funding; the University of Pennsylvania received $1.8 billion and Yale University received $898.7 million during 2024.
Not far behind were Cornell University, receiving $825.5 million in fiscal year 2024, and Harvard University, which received $686.5 million. Princeton University took in $455 million, Brown University reported "more than $254 million" and, according to USA Spending, Dartmouth received $141.9 million in 2024.
The funds that universities receive from the federal government are often in the form of grants and used for research and development, facility and administrative costs and student aid. The Trump administration has frozen billions in federal funding to colleges and universities that do not comply with the president's executive orders to protect Jewish students from hate and dismantle DEI policies.
The White House did not respond to a request for comment.
Each of the eight total Ivy League schools have mental health resources ranging from counseling hotlines and centers to student-run support groups.
Suicide continues to be a leading cause of death within the United States, with 49,000 people dying by suicide in 2023, according to the latest data from the Centers for Disease Control and Prevention (CDC). Suicide rates increased 37% between 2000-2018 and decreased 5% between 2018-2020 before returning to their peak in 2022, according to the agency.
"I think one of the most important things is thinking about going back to the basics of, hey, if you know that Billy down the hall lives alone in an individual room and you haven't seen him in a day or two, he hasn't attended Psych 101 with you … knock on his door, ask, how are you? Can I get you something? Just going back to the basics of loving your neighbor," Grinman said.
Fox News Digital's Rachel del Guidice and Jacqliene Mangini contributed to this report.Original article source: Ivy League suicides, Princeton's 8th student death in 4 years expose crisis at elite schools
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
'Love Is Blind' Alum Marshall Glaze Details Struggle with Suicidal Ideation
Warning: This story discusses suicide. If you or someone you know is in crisis, call 988 to reach the Suicide and Crisis Lifeline. You can also call the network, previously known as the National Suicide Prevention Lifeline, at 800-273-8255, text HOME to 741741 or visit for additional resources. A "Love Is Blind" alum is sharing a powerful message about mental health. Marshall Glaze, who appeared on Season 4 of the Netflix dating series, just opened up about a dark period in his life that occurred last year. While appearing on the latest episode of "Love Is Blind" alum AD Smith's "What's The Reality?" podcast, Glaze acknowledged that he experienced suicidal thoughts amid a mental health crisis. 'Last year was just very tough for me mentally, and I was going to take my own life,' he said. 'It just got to a point where, I had always been morbidly curious, but never thought about how to do it. And then, one day, I'm just down in the dumps, just crazy depressed. I feel like nothing is going right. That's what my internal monologue is telling me.' Glaze went on to explain that his internal "voices" and "darkness" kept getting "a little bit louder" and "a little bit darker." 'It just felt like the walls were just getting closer and closer and closer, and nothing — no favorite meal, no favorite movie, no favorite song — could lift me out of that. And I knew I had a problem when I was OK with, this particular time that I talked to my mom, I was OK with that being the last time I talked to her,' he recalled. Glaze, who noted that he typically talks to his mom several times a day, said he then knew something was wrong. 'I was going to do what I felt like I had to do, but I couldn't,' he said. Glaze said he decided to take a walk in his Seattle neighborhood to clear his head and said this simple act encouraged him to get help. 'I lived on a very busy street in downtown Seattle, and at any time of the day, there's buses, cars, bikes, people walking, and nobody was out there — no cars, no buses, no bikes, no people, nothing," he said. After walking around in the deserted area, Glaze returned home and had an important realization. "I (was like), 'I want to live,'" he recalled. Smith told Glaze she was happy he decided to go on a walk and get fresh perspective. In response he said, "Thank you. Me too. I'm glad I'm here." "I'm glad you're here. We're all glad you're here," she said. While opening up about his decision to go public with his mental health challenges, Glaze acknowledged that the experience helps him "heal." "I hope that someone out there can resonate with that and choose life," he said. "Someone will for sure," Smith said. This article was originally published on


Time Business News
19 hours ago
- Time Business News
Nurturing Young Minds Through Language: The Power of Bilingual Daycare in Early Childhood Development
In today's increasingly globalized world, bilingualism is no longer just a desirable skill—it's an essential one. From improved cognitive development to increased cultural awareness, the benefits of early exposure to a second language are both immediate and long-lasting. For families in Houston, choosing a daycare that incorporates language learning into its curriculum can be a game-changer. That's why more parents are turning to trusted providers like ABC Daycare Houston—a top-rated Bilingual Daycare known for its nurturing environment and holistic approach to early childhood education. Research shows that children who are exposed to more than one language at an early age develop stronger problem-solving skills, better memory retention, and greater empathy toward other cultures. In a bilingual daycare setting, language learning isn't treated as a separate subject—it's embedded in everyday activities. This natural, immersive approach helps children develop fluency in both languages without even realizing they're learning. Benefits of bilingual daycare include: Enhanced Brain Development : Studies indicate that bilingual children have more flexible thinking and superior executive function skills. : Studies indicate that bilingual children have more flexible thinking and superior executive function skills. Improved Academic Performance : Early exposure to a second language correlates with higher performance in reading, writing, and math later on. : Early exposure to a second language correlates with higher performance in reading, writing, and math later on. Cultural Appreciation : Learning a new language often includes understanding different traditions, holidays, and perspectives, broadening a child's worldview. : Learning a new language often includes understanding different traditions, holidays, and perspectives, broadening a child's worldview. Stronger Communication Skills: Kids become more adept at switching between languages and communicating with a wider range of people. For parents seeking these benefits, finding a quality bilingual learning environment is key. One of the most effective methods for fostering bilingualism in young children is through Spanish immersion. Unlike traditional classrooms that might only offer Spanish once or twice a week, a Spanish Immersion Daycare provides a fully immersive experience where Spanish is spoken throughout the day. This constant exposure helps children absorb vocabulary and grammar in the most natural way possible—through play, storytelling, music, and conversation. ABC Daycare Houston's Spanish immersion program is designed to cater to both native English and Spanish speakers, ensuring that each child is supported and challenged at the right level. Teachers are fluent in Spanish and trained in early childhood education, combining linguistic skills with a deep understanding of how young children learn best. Language learning is just one aspect of ABC Daycare Houston's comprehensive early education philosophy. The center also emphasizes social, emotional, and physical development to ensure every child thrives. Their daily routines include: Creative Play : Encouraging imagination through art, dress-up, building blocks, and more. : Encouraging imagination through art, dress-up, building blocks, and more. Outdoor Activities : Promoting physical health and motor skills through guided play and exploration. : Promoting physical health and motor skills through guided play and exploration. Literacy Time : Reading books in both English and Spanish to build vocabulary and comprehension. : Reading books in both English and Spanish to build vocabulary and comprehension. Cultural Enrichment : Celebrating cultural events and traditions to foster inclusivity and curiosity. : Celebrating cultural events and traditions to foster inclusivity and curiosity. Nutritious Meals: Providing healthy, balanced meals to support growing bodies and minds. Each activity is thoughtfully designed to reinforce language skills while supporting the overall development of the child. What sets ABC Daycare Houston apart is their commitment to providing a safe, inclusive, and enriching environment for children. With small class sizes, experienced staff, and a warm community feel, parents can rest assured that their children are not only learning but also enjoying their day in a secure and loving setting. Key reasons families choose ABC Daycare include: Certified and Caring Staff : Educators who are passionate about bilingual learning and child development. : Educators who are passionate about bilingual learning and child development. Engaging Curriculum : Lessons and activities designed to be both fun and educational. : Lessons and activities designed to be both fun and educational. Safe Environment : Adherence to the highest standards of cleanliness, security, and care. : Adherence to the highest standards of cleanliness, security, and care. Parent Communication: Regular updates and open lines of communication to keep families informed and involved. Bilingual education is an investment in your child's future—and there's no better time to start than during the early years. By enrolling your child in a bilingual or Spanish Immersion Daycare, you're giving them a strong foundation for academic success, cultural awareness, and lifelong communication skills. If you're looking for a trusted, high-quality bilingual daycare in Houston, we encourage you to explore the offerings at ABC Daycare Houston. Their experienced team is ready to welcome your child into a vibrant, supportive environment where learning and language go hand in hand. TIME BUSINESS NEWS


Associated Press
21 hours ago
- Associated Press
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 6, 2025-- Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo 1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data 1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group. 1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo. Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 2. Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation 3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home. 'We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials,' said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. 'Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease.' The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN 1. 'The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology,' said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. 'The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN.' About the VISIONARY Study The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo 1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months 1. About Sibeprenlimab Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation 8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD 3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss. About IgAN and APRIL IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients 9,10,11. IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients 10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5. APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys 5. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a 'big venture' company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at About Visterra Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit References View source version on CONTACT: Contacts for MediaOtsuka in the Murphy Corporate Communications Otsuka America Pharmaceutical, Inc. [email protected]+1 609 249 7262Otsuka in JapanJeffrey Gilbert Leader, Pharmaceutical PR Otsuka Pharmaceutical Co., Ltd. [email protected]+81 3 6361 7379 KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC NEW JERSEY INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS OTHER HEALTH SOURCE: Otsuka Pharmaceutical Co., Ltd. Copyright Business Wire 2025. PUB: 06/06/2025 06:00 AM/DISC: 06/06/2025 05:58 AM